Literature DB >> 8178553

Vaccination against rabies: construction and characterization of SAG2, a double avirulent derivative of SADBern.

F Lafay1, J Bénéjean, C Tuffereau, A Flamand, P Coulon.   

Abstract

A double avirulent mutant was isolated from the SADBern strain of rabies virus by two successive selection steps using neutralizing anti-glycoprotein monoclonal antibodies. Both mutations affect the triplet coding for amino acid 333 of the glycoprotein. The resulting virus, called SAG2, has a glutamate coded by GAA in position 333 instead of an arginine. This new codon differs by two nucleotides from all the arginine triplets. SAG2 is avirulent in adult mice by intracerebral and intramuscular routes and it protects mice against a challenge by the CVS strain. This double mutant is still avirulent after three successive passages in suckling mouse brain or after ten successive cycles of multiplication in cell culture. Because it is protective and genetically stable, SAG2 represents an improvement on SAG1 which is already used for oral vaccination of foxes in Switzerland and France. It could also be a candidate for oral vaccination of dogs against rabies.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8178553     DOI: 10.1016/0264-410x(94)90095-7

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  17 in total

1.  Rabies virus infects mouse and human lymphocytes and induces apoptosis.

Authors:  M I Thoulouze; M Lafage; J A Montano-Hirose; M Lafon
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

2.  An avirulent mutant of rabies virus is unable to infect motoneurons in vivo and in vitro.

Authors:  P Coulon; J P Ternaux; A Flamand; C Tuffereau
Journal:  J Virol       Date:  1998-01       Impact factor: 5.103

3.  Extensive attenuation of rabies virus by simultaneously modifying the dynein light chain binding site in the P protein and replacing Arg333 in the G protein.

Authors:  T Mebatsion
Journal:  J Virol       Date:  2001-12       Impact factor: 5.103

4.  Structure of the rabies virus glycoprotein trimer bound to a prefusion-specific neutralizing antibody.

Authors:  Heather M Callaway; Dawid Zyla; Florence Larrous; Guilherme Dias de Melo; Kathryn M Hastie; Ruben Diaz Avalos; Alyssa Agarwal; Davide Corti; Hervé Bourhy; Erica Ollmann Saphire
Journal:  Sci Adv       Date:  2022-06-17       Impact factor: 14.957

5.  Low-affinity nerve-growth factor receptor (P75NTR) can serve as a receptor for rabies virus.

Authors:  C Tuffereau; J Bénéjean; D Blondel; B Kieffer; A Flamand
Journal:  EMBO J       Date:  1998-12-15       Impact factor: 11.598

6.  Cross-protection of mice against a global spectrum of rabies virus variants.

Authors:  D L Lodmell; J S Smith; J J Esposito; L C Ewalt
Journal:  J Virol       Date:  1995-08       Impact factor: 5.103

7.  A novel oral rabies vaccine enhances the immunogenicity through increasing dendritic cells activation and germinal center formation by expressing U-OMP19 in a mouse model.

Authors:  Jianqing Zhao; Yijing Zhang; Yixi Chen; Juntao Zhang; Jie Pei; Min Cui; Zhen F Fu; Ling Zhao; Ming Zhou
Journal:  Emerg Microbes Infect       Date:  2021-12       Impact factor: 7.163

8.  Eliminating rabies in Estonia.

Authors:  Florence Cliquet; Emmanuelle Robardet; Kylli Must; Marjana Laine; Katrin Peik; Evelyne Picard-Meyer; Anne-Laure Guiot; Enel Niin
Journal:  PLoS Negl Trop Dis       Date:  2012-02-28

9.  Recombinant rabies viruses expressing GM-CSF or flagellin are effective vaccines for both intramuscular and oral immunizations.

Authors:  Ming Zhou; Guoqing Zhang; Guiping Ren; Clement W Gnanadurai; Zhenguang Li; Qingqing Chai; Yang Yang; Christina M Leyson; Wenxue Wu; Min Cui; Zhen F Fu
Journal:  PLoS One       Date:  2013-05-20       Impact factor: 3.240

10.  Spatio-temporal Use of Oral Rabies Vaccines in Fox Rabies Elimination Programmes in Europe.

Authors:  Thomas F Müller; Ronald Schröder; Patrick Wysocki; Thomas C Mettenleiter; Conrad M Freuling
Journal:  PLoS Negl Trop Dis       Date:  2015-08-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.